https://www.selleckchem.com/products/tpx-0005.html
Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that inhibits the p19 subunit of interleukin 23 from interacting with its receptor for the treatment of moderate to severe plaque psoriasis. The aim of this Phase I biopharmaceutics bridging study was to evaluate the pharmacokinetic comparability, immunogenicity, and tolerability of the risankizumab 90mg/mL prefilled syringe (PFS) and the risankizumab 150mg/mL PFS and auto-injector (AI) in healthy subjects. Healthy subjects received one 150-mg dose of risankizumab in 1 o
Like
Comment
Share
